Histamine dihydrochloride oral - EpiCept Corporation

Drug Profile

Histamine dihydrochloride oral - EpiCept Corporation

Alternative Names: HD-O

Latest Information Update: 26 Apr 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Maxim Pharmaceuticals
  • Class Antineoplastics; Antivirals; Imidazoles; Small molecules
  • Mechanism of Action Histamine H2 receptor agonists; Oxygen radical formation antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Alcoholic hepatitis; Hepatitis C; Non-alcoholic steatohepatitis

Most Recent Events

  • 09 Jan 2006 Maxim Pharmaceuticals has been acquired and merged into EpiCept Corporation
  • 23 Jun 2004 Histamine dihydrochloride oral is available for licensing and development (http://www.maxim.com/)
  • 21 May 2004 Data presented at the Digestive Disease Week-2004 (DDW-2004) have been added to the Liver Disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top